Fecal transplant for chronic heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether transferring healthy gut bacteria (fecal microbiota transplant) can help people with chronic heart failure feel better and improve their heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure with reduced or preserved ejection fraction and are in class II–IV (symptoms with mild to moderate activity or at rest).
- Your heart failure medications have been stable for at least 1 month.
- You are able to swallow capsules.
- You can provide a blood sample and a stool sample.
- You are willing to follow all study procedures and stay in touch with the study team for follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether transplanting healthy gut bacteria can help older adults with heart failure that has a preserved ejection fraction (HFpEF). Researchers think the gut microbiome may play a role in heart function and hope this treatment could improve symptoms and quality of life.
This trial tests whether transplanting healthy gut bacteria can help prevent confusion and brain problems caused by liver disease. You would receive either the bacteria treatment or standard medications to see if it reduces these episodes.
This trial studies using a fecal microbiota transplant (FMT)—healthy gut bacteria moved from a screened donor—to help treat recurring or hard-to-control C. difficile infection. It may help restore a healthier gut environment when standard treatments keep failing or the infection returns.
This study tests whether transplanting healthy gut bacteria, after a short course of antibiotics and with fiber supplements, can improve symptoms of pulmonary hypertension. It is an early-phase trial to see if the treatment is safe and helpful.
This trial tests whether a special combination of antibiotics, fecal transplant (gut bacteria from healthy donors), and a fiber supplement can help people with pulmonary arterial hypertension (PAH). It aims to see if improving gut health can improve PAH symptoms and overall well-being.
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hear when a new Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.